logo image
search icon
Global TNF Biosimilars Market

TNF Biosimilars Market Size, Share & Trends Analysis Report By Drug (Adalimumab Biosimilar, Infliximab Biosimilar, Certolizumab Biosimilar, Etanercept Biosimilar, and Golimumab Biosimilar), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy), Region And Segment Forecasts, 2023-2031.

Report ID : 1072 | Published : 2024-03-14 | Pages: 180 | Format: PDF/EXCEL

The TNF Biosimilars Market is expected to grow at a 14.90 % CAGR during the forecast period for 2023-2031.

TNF Biosimilars Market

Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called TNF blockers. Currently only five TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is the king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of TNF biosimilar market. Moreover, the rising incidence and prevalence of rheumatic disease and switching trends from traditional treatment to biologic therapy have increased the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.

Market Segmentation

The global TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of treatment the global market is further sub segmented into adalimumab biosimilar, infliximab biosimilar, certolizumab biosimilar, etanercept biosimilar, and golimumab biosimilar. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. Humira is protected with more than 100 patents in US which make the entry of biosimilars complicated in the US market however, biosimilar of adalimumab is expected to launch in the US by 2023 and in Europe in 2018 which drives the growth of the market during forecast period. TNF Inhibitors market is already saturated thus certolizumab biosimilar and golimumab biosimilar segments are expected to hold minimal share of the market due to late entry of biosimilars in the market. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to the increase in number internet user and ease of use.

At regional level, the global TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demand for biosimilars propels the growth of the market in the region. Asia Pacific is the third promising revenue contributor which is expected to grow at a rapid pace in upcoming year. Countries such as Japan, India, and China are major contributors to this market. Emerging and colossal population base countries such as China and India offer tremendous market opportunities for the TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of TNF in low-income countries.

Competitive Landscape

Some of The Key Players in The TNF Biosimilars Market:

  • Amgen
  • Sandoz
  • Boehringer Ingelheim
  • Pfizer
  • Samsung Bioepis
  • Coherus Biosciences
  • Celltrion
  • Nichi-Iko
  • Other Prominent Players

The TNF Biosimilars Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 14.90 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Drug, By Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko, and others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global TNF Biosimilars Market Snapshot

Chapter 4. Global TNF Biosimilars Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Estimates & Trend Analysis

5.1. By Drug & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Drug:

5.2.1. Adalimumab biosimilar

5.2.2. Infliximab biosimilar

5.2.3. Certolizumab biosimilar

5.2.4. Etanercept biosimilar

5.2.5. Golimumab biosimilar

Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis

6.1. By Distribution Channel & Market Share, 2022 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Retail Pharmacy

6.2.3. Online Pharmacy

Chapter 7. TNF Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America TNF Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug, 2022 - 2030

7.1.2. North America TNF Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.1.3. North America TNF Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030 

7.2. Europe

7.2.1. Europe TNF Biosimilars Market revenue (US$ Million) By Drug, 2022 - 2030

7.2.2. Europe TNF Biosimilars Market revenue (US$ Million) By Distribution Channel, 2022 - 2030

7.2.3. Europe TNF Biosimilars Market revenue (US$ Million) by country, 2022 - 2030

7.3. Asia Pacific

7.3.1. Asia Pacific TNF Biosimilars Market revenue (US$ Million) By Drug, 2022 - 2030

7.3.2. Asia Pacific TNF Biosimilars Market revenue (US$ Million) By Distribution Channel, 2022 - 2030

7.3.3. Asia Pacific TNF Biosimilars Market revenue (US$ Million) by country, 2022 - 2030

7.4. Latin America

7.4.1. Latin America TNF Biosimilars Market revenue (US$ Million) By Drug, (US$ Million)

7.4.2. Latin America TNF Biosimilars Market revenue (US$ Million) By Distribution Channel, (US$ Million)

7.4.3. Latin America TNF Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa TNF Biosimilars Market revenue (US$ Million) By Drug, (US$ Million)

7.5.2. Middle East & Africa TNF Biosimilars Market revenue (US$ Million) By Distribution Channel, (US$ Million)

7.5.3. Middle East & Africa TNF Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Amgen

8.2.2. Sandoz

8.2.3. Boehringer Ingelheim

8.2.4. Pfizer

8.2.5. Samsung Bioepis

8.2.6. Coherus Biosciences

8.2.7. Celltrion

8.2.8. Nichi-Iko

8.2.9. Other Key Players

Segmentation of TNF Biosimilars Market

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030), by Drug

  • Adalimumab biosimilar
  • Infliximab biosimilar
  • Certolizumab biosimilar
  • Etanercept biosimilar
  • Golimumab biosimilar

TNF Biosimilars Market

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030), by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the TNF Biosimilars Market Growth?

Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko, and others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach